Scandinavian ChemoTech welcomes new energy to its management
As part of increasing the production rate and at the same time improving communication, Scandinavian ChemoTech is implementing changes in management.
Jonathan Furelid, started as a consultant with us in June and will have the role of Head of Investor Relations and join the management as of today.
Anders Johnsson, was assigned the role of Head of Production during the summer and will now focus fully on managing and streamlining all our production. The commercial responsibilities for Vetiqure, that Anders held, will in the future be managed by our CEO Mohan Frick.
Dr Suhail Mufti, has been added as "local dedicated partner" in India and takes over from Ashim Purohit who has chosen to leave his role as Director. We are required by Indian law to have a local representative and we are very happy that Dr Suhail has undertaken this mission. Suhail also steps in as Medical Advisor and is medically responsible for our studies, where the study at AIIMS is closest in time.
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
ir@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
